Brief: Hepion Pharmaceuticals' NASH drug meets main goal in mid-stage trial
22/05/2023 13:04
May 22 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS’ PHASE 2 ‘ALTITUDE-NASH’ TRIAL
ACHIEVES
PRIMARY AND SECONDARY ENDPOINTS, INCLUDING IMPROVEMENT IN LIVER
FUNCTION AND MULTIPLE NASH BIOMARKERS
Source text for Eikon: ID:nGNX1Rrqn
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement